A method for ligand screening by automated nano-electrospray ionization mass spectrometry (nano-ESI/MS) is described. The core of the system consisted of a chip-based platform for automated sample delivery from a 96-well plate and subsequent analysis based on noncovalent interactions. Human fatty acid binding protein, H-FABP (heart) and A-FABP (adipose), with small potential ligands was analyzed. The technique has been compared with a previously reported method based on nuclear magnetic resonance (NMR), and excellent correlation with the found hits was obtained. In the current MS screening method, the cycle time per sample was 1.1 min, which is approximately 50 times faster than NMR for single compounds and approximately 5 times faster for compound mixtures. High reproducibility was achieved, and the protein consumption was in the range of 88 to 100 picomoles per sample. Furthermore, a novel protocol for preparation of A-FABP without the natural ligand is presented. The described screening approach is suitable for ligand screening very early in the drug discovery process before conventional high-throughput screens (HTS) are developed and/or used as a secondary screening for ligands identified by
INTRODUCTION
T HE VAST NUMBER OF NEW DRUG CANDIDATES produced by high-throughput chemistry (HTC) requires fast and efficient methods both for characterization of the individual compounds and their affinity to target molecules. Often, high-throughput screening (HTS) methods 1 based on biological assays with fluorescence detection, radioactive dyes, ELISA, and so on are used to investigate the binding properties for a large number of library compounds against a target molecule such as a protein, an enzyme, DNA, and so forth. Hits from the screening process are further optimized by an iterative process that has been termed lead optimization. 2 Lead optimization is a process used to increase the understanding of the structure-activity relationship and to facilitate the incorporation of all desirable properties required to make a drug. One of the goals is to identify compounds with a high binding affinity to the target molecule, which enables the use of lower dosages of the drug to minimize potential side effects. The development of HTS is often a very time-consuming (weeks to months) process. On the other hand, a large number of analyses can be performed in parallel, resulting in a high final throughput with low protein consumption per analysis. One way to accelerate drug discovery and thus decrease the time for the overall drug development process is to perform drug screening at an early stage of the process. A prerequisite for such an approach is the availability of sensitive analytical methods.
Electrospray ionization mass spectrometry (ESI-MS) is a soft ionization technique with high sensitivity. A further increase in sensitivity and the possibility to extend the analysis time for small samples volumes (< 1 µL) became possible after the introduction of the nano-electrospray ionization technology (nano-ESI) by Wilm and Mann. 3 Ligand screening by ESI-MS has been described by several authors. It has been shown that this is a powerful technique for screening ligands against large target molecules (M w > 35 kDa). 4 Early applications of noncovalent interactions have been demonstrated by Ganem et al. 5 and Smith and Light-Wahl. 6 During the past 3 to 4 years, the number of papers published in the area has accelerated, 7, 8 and an extensive review on the subject has been published by Siegel. 9 Time-of-flight mass spectrometry offers the sensitivity needed for screening when only small amounts of protein are available. Further advantages of measuring noncovalent interactions by ESI-MS are 1) that method development only involves optimization of MS parameters because the protein is free in solution and not covalently bound or modified and 2) that stoichiometric information can be obtained.
Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR/MS) with ESI has successfully been applied to highthroughput affinity screening. The high resolution of this type of MS system has facilitated the analysis of multiple ligands simultaneously. Sannes-Lowery et al. 10 used this technique for the identification of small molecular mass ligands interacting with multi-RNA targets, which was named MASS (multitarget affinity/specificity screening). Furthermore, these authors demonstrated the possibility of detecting specific binding and were able to determine dissociation constants (K d ). FT-ICR/MS in combination with microelectrospray has been used for the simultaneous analysis of a 324-member peptide library screened against the Hck Src homology 2 domain receptor. 11 The combination of capillary isoelectric focusing-ESI/MS to screen high-affinity ligands against the Src SH2 domain by noncovalent interaction was shown by Lyubarskaya et al. 12 These authors used online selection and online structural identification of strongly bound ligands. Greig and Robinson 13 described detection of oligonucleotide-ligand complexes by ESI-MS (DOLCE-MS) as a component of HTS. Both the sample preparation and data acquisition were automated, allowing analysis of up to 1000 samples per week. Jiang and coworkers 14 described a microfluidic device for drug screening based on noncovalent binding. The methodology included affinity capture, concentration, and identification of liberated ligands by ESI-MS. Nano-ESI has been used for screening potential pigments from anthocyanins in red wine based on their MS/MS spectra, as shown by Hayasaka and Asenstorfer. 15 Cytoplasmic fatty acid binding proteins (FABPs) are responsible for the transport of fatty acids and other compounds with low cytosolic solubility. The protein of interest in this study, A-FABP, constitutes 2% to 5% of the soluble protein in adipose tissue. This is the only tissue in which A-FABP is appreciably expressed. 16 Dietary obese A-FABP knockout mice (aP2 -/-) show reduced insulin resistance. 17 A drug that inhibits the binding of fatty acids to A-FABP could also have a similar effect. To be effective, the drug should be selective for A-FABP because there are several FABPs present in different tissues that are structurally and sequentially similar to A-FABP. If the drug is not sufficiently selective, these other FABPs could be inhibited. 18 In the present study, binding to H-FABP is used as a measure of the selectivity for A-FABP over other FABPs. H-FABP is the FABP that shows the second highest sequence homology to A-FABP, with 64% sequence identity (M-FABP [myelin] is the most homolo-gous, with 66% sequence identity). H-FABP is present in heart, kidney, skeletal muscle, and other tissues. 18 In the present work, an automated nano-ESI was used for protein-ligand screening based on noncovalent interaction applied to human FABPs. The core of the system was a chip-based platform for automated sample infusion and ionization from a 96-well plate. Using this approach, a noncovalent complex of adipose FABP could be detected, which was not possible when using nano-ESI with conventional pulled glass capillaries. The approach as described combined a short cycle time with low protein consumption per analysis. The results from this work are compared to a recently performed study using nuclear magnetic resonance (NMR)-based screening on the same set of ligands. In addition, we present a novel protocol for preparation of fatty acid free adipose (FABP) with high recovery and few purification steps.
EXPERIMENTAL SECTION

Materials
Water-soluble potential ligands (0.5 mM in DMSO; stock solution) with a molecular mass range between 150 and 360 Da were selected from the in-house compound collection. Ammonium acetate (NH 4 OAc) was from Merck (Darmstadt, Germany). Water was purified in a Millipore (Bedford, MA) gradient purifier. H-FABP and A-FABP were dissolved in 10 mM NH 4 OAc in water, giving a final concentration of 23 and 27 µM, respectively. When ligands were used, they were added in 3-to 4-fold excess compared to protein concentrations. A sample volume of 4 µL was dispensed into the 96-well plate. The solutions for dissolving the chemicals were filtered through a 0.45-µm nylon filter from SGE (Austin, TX).
Protein expression and purification
Full-length recombinant human adipocyte fatty acid binding protein (A-FABP) was produced in Escherichia coli BL21(DE3) cells (expression vector pET36b+). All cell growth was conducted in an incubator at 37°C and 200 rpm stirring. The cells were grown in a day in a 5-mL Luria-Bertani medium, and a small aliquot of the cell suspension (0.1 mL) was added to 0.1 L of minimal medium containing glycerol and ( 15 NH 4 ) 2 SO 4 in a 2.5-L shake flask. After overnight growth, the cell suspension was diluted with minimal medium to 1 L, and at OD 600~0 .5, protein production was induced with 1 mM isopropyl β-D-thiogalacto pyranoside (IPTG). The cells were harvested after 22 h.
The cell pellet was resuspended in ice-cold 300 mL of 10mM Tris buffer, 1 mM tris (carboxy ethyl) phosphine (TCEP), pH 8.5, and then ultrasonicated continuously in a water-cooled flow cell. The homogenate was spun down for 1 h at 30,000 g at 8°C. All subsequent steps were carried out at room temperature. The cell pellet was dissolved in 180 mL 8 M urea, 10mM Tris buffer, 1 mM TCEP, pH 8.5, by vigorous stirring. After centrifugation for 20 min at 30,000 g, the supernatant was applied to a 6-mL Resource Q (Pharmacia Biotech, Uppsala, Sweden) column. The capacity of the column was sufficient to retain molecules with a higher net negative charge than A-FABP. The protein of interest was found in the flow-through fraction. A-FABP was refolded by 10 times dilution with 10 mM Tris buffer and 1 mM TCEP, pH 8.5. The solution was then applied to a 200-mL Q Sepharose FF (Pharmacia Biotech) column. The column was washed with 0.4 L buffer, and pure and folded A-FABP was eluted as the first peak (centered at conductivity 4 mS/cm) of a 0-to 0.1-M NaCl gradient using 0.6 L buffer. The flow rate over the column was 0.6 L/h. The protein solution was concentrated to 19 g/L using a Jumbosep concentrator with a 10K MWCO filter obtained from Pallfiltron (Ann Arbor, MI). This procedure yielded 95 mg A-FABP (from a 1-L culture) free from fatty acid, as analyzed by ESI-MS. The purity was > 95%, as determined by SDS-PAGE.
Full-length recombinant human H-FABP with a C-terminal His 8 -tag in the same expression system as A-FABP was fermentor produced. The cell suspension was ultrasonicated continuously in a water-cooled flow cell, and the extract was centrifuged. The supernatant was loaded on a 51-mL, Ni 2+ -loaded, Poros 20 IMAC column (Applied Biosystems) and eluted with a 0-to 0.2-M imidazole gradient in 50 mM sodium phosphate and 0.5 M NaCl (pH 8.0). The obtained 20-mL H-FABP fraction was applied with 5-mL injections on a Superdex 75 pg XK26/60 column, yielding the pure protein (> 95%, as determined by SDS-PAGE). The mobile phase, which consisted of 20 mM HEPES, 100 mM NaCl, and 100 µM EDTA, was pumped with a flow rate of 54 mL/h.
The nonvolatile buffer used for the H-FABP and A-FABP during the purification step was exchanged to 10 mM NH 4 OAc in water by dialysis overnight at ambient temperature with a 0.5-mL Slide-A-Lyzer dialysis cassette from Pierce (Rockford, IL).
Mass spectrometry
The analyses were performed on a Q-TOF 1 instrument (Micromass, Manchester, UK) equipped with a nano-electrospray system model NanoMate 100 from Advion BioSciences (Ithaca, NY). The operating conditions for the nano-electrospray interface and the mass spectrometer were as follows: spray voltage 1650 V, cone voltage 30 V, 0.6 psi sample pressure, desolvation gas temperature 60°C, source block temperature 30°C, and desolvation gas flow 20 L/h. Full-scan mass spectra of positive ions were recorded in the profile mode. The mass range between 1000 and 4000 Da was recorded at a resolution of 5800 (FWHM). The accumulation time was 2 sec/spectrum. The pressure between the cone and the extraction lens was raised to 1.7e-5 bar (measured in the quadrupole analyzer) by partially closing the valve of the rotary pump. Furthermore, the collision gas (argon) pressure was activated, resulting in a 3.3e-5 bar quadrupole analyzer pressure. The collision energy in the collision cell was set to 4 V. The rationale behind the increased pressure settings has been described in recently published articles. 19, 20 All data were processed using the Masslynx software, version 3.5, from Micromass.
Automated nano-electrospray platform
The NanoMate and ESI chip from Advion BioSciences (Ithaca, NY) were used for automated nano-electrospray analyses. The NanoMate first aspirates sample from a conventional 96-well microplate using a disposable, conductive pipette tip and then delivers the sample to the inlet side of the ESI chip, forming a pressure seal around a through-wafer channel. The ESI chip consists of a 10 × 10 array of inlets to a through-wafer channel on 1 planar surface and a corresponding 10 × 10 array of nozzles on the opposite side, with each through-chip channel leading to a nozzle. Nanoelectrospray was initiated by a 1.2-to 1.8-kV spray voltage and a 0.2-to 0.6-psi pressure being applied to the sample in the pipette tip. A separate nozzle was used for each sample. After analysis, the pipette tip was ejected.
RESULTS AND DISCUSSION
Expression and purification of A-FABP
When A-FABP-expressing bacteria are grown in Luria-Bertani medium, high levels of overexpressed A-FABP are achieved without IPTG induction, and the protein is obtained in a soluble form. However, contrary to a previous report by Constantine et al., 21 no protein overexpression was obtained in minimal medium with glucose as the carbon source. One reason for this discrepancy could be that these authors used the expression vector pET11a, whereas pET36b+ was used in the present study. Another possible explanation for the different behavior could be the composition of the minimal media. High levels of overexpression of A-FABP are obtained when glucose is exchanged for glycerol. In this case, A-FABP was obtained in the form of insoluble inclusion bodies. A similar behavior has been reported for B-FABP (brain). At 37°C, the protein was expressed as inclusion bodies, whereas expression at 22°C gave soluble protein. 22 The use of 15 N ammonium sulfate as a nitrogen source enables verification of the success of the refolding procedure through the recording of a 15 N hetero-nuclear single-quantum coherence (HSQC) spectrum of A-FABP. The resulting spectrum shows the chemical shift dispersion expected for a folded protein (data not shown). Addition of a molar excess of BVT.1961 results in a spectrum that is identical to the spectrum of the 1:1 A-FABP (see the BVT.1961 complex shown in Fig. 7 of van Dongen et al., 23 in which A-FABP was purified from the soluble fraction of the lysate). This proves that the refolded A-FABP shows the same mode of binding of BVT.1961 as recombinant protein purified from the soluble fraction of E. coli. The purification of A-FABP from inclusion bodies presented here has advantages compared to the purification protocol of Constantine et al. First, and most important, is the fact that according to experience in our lab, using a Lipidex column will not fully delipidate A-FABP, whereas our protocol will yield essentially fatty acid free A-FABP, as confirmed by electrospray-mass spectrometry (ES-MS), without the need for a specific delipidation step. The protein is denatured inside the cells and cannot bind fatty acids in the binding cavity of the Automated Nano-Electrospray Mass Spectrometry folded protein. Second, our protocol contains fewer purification steps. Third, the protein yield is more than 7 times higher than the previously reported protocol. 21 Ligand screening NMR spectroscopy has successfully been applied to proteinligand screening. 24 van Dongen et al. 23 recently introduced a new approach called structure-based screening. First, NMR was used as a generic binding assay. In this case, a 1 H 1D relaxation filter experiment was applied to a mixture of A-FABP and potential ligands, whereby binding was detected by increases in the ligand NMR line widths caused by the reduced tumbling rate. Second, hits found in the first step were ranked according to their affinity to the protein to obtain a crude structure-activity relationship. Finally, the structure of the chosen hit was optimized by a structure-based design with respect to affinity and selectivity. Furthermore, the NMR screening results were in good correlation with the used fluorescence displacement assay for obtaining the IC 50 values of all the ligands.
An important aspect of the screening procedure is the cycle time for the analysis. Compared to our MS screening method, NMR is relatively slow. The acquisition time for NMR screening by a 1 H 1D relaxation filter experiment is approximately 60 min. 23 On the other hand, mixtures of compounds (up to 10 potential ligands in this case) were successfully analyzed. Other authors have reported NMR screens that use 100 compounds simultaneously. 25 FT-ICR/ MS has also been used for ligand screening of large libraries. Wigger et al. 11 analyzed a peptide library with 324 peptides simultaneously against the Hck Src homology 2 domain receptor.
Noncovalent interactions
In our experience, a protein and a ligand used in interaction studies by mass spectrometry must have certain chemical and physical properties. First, the solubility in 10 mM NH 4 OAc (or concentrations up to 100-200 mM NH 4 OAc, if necessary) should be in the range of 1 to 100 µM. Second, the purity of the protein must be higher than > 90% to avoid spectra interpretation difficulties. Third, the limitation regarding the molecular mass of the target protein and ligand depends on the resolution of the MS instrumentation. The concentrations of the proteins and ligands must be carefully optimized to avoid nonspecific interaction. Furthermore, if determination of the K d values is the goal, the concentrations of the ligands must be well above the K d to achieve adequate resolution in K d for the competitive ligand. However, in the present study, we were interested in ligand binding screening instead of determining the K d values. Therefore, the concentrations of the protein and ligands were chosen to produce adequate response in the mass spectrometer. On the other hand, the concentration could easily be decreased by a factor of 2 to 3 for single-ligand analysis. The time lap for mixing protein and ligands and analysis of the first sample in the 96-well plate was about 10 min. Because the interaction is momentary, 10 min is enough for the equilibrium to be established. Furthermore, it was determined that once the equilibrium was established, the ratio between protein and the complex would be constant throughout the analysis (175 min) of the whole 96-well plate (data not shown).
Careful optimization of the mass spectrometric and interface settings (cone voltage, source block temperature, desolvation gas temperature, pressure in the ESI region, and collision gas pressure) was required to maintain the intact H-FABP and A-FABP complexes in the gas phase for analysis. The interaction between FABPs and ligands is partly hydrophobic, 16 which causes the binding to be weakened in the gas phase when the amount of surrounding buffer ions is low or absent. 26 The interaction between A-FABP and potential ligands could not be detected when using conventional pulled glass capillaries for nano-ESI analysis, but the complexes could easily be evaluated with use of the automated chipbased nano-ESI platform. We believe that the lower sensitivity for the pulled capillaries can be attributed to the formation of sodium adduct ions on the protein, which was shown recently. 20 The contamination of protein by undesired adduct ions can be kept low if contact with laboratory glassware (sample vials, etc.) and biological buffers containing low molecular mass cations is avoided. Unfortunately, this is practically impossible during the process of cloning, expression, and purification of proteins. However, removal of adduct ions can be performed online or offline by dialysis. In the present work, the most practical approach was offline dialysis before the protein and the ligands were mixed. All subsequent sample preparation and handling was thereafter performed in Eppendorf tubes. An advantage offered by the automated nano-electrospray system includes the ability to conserve samples not consumed in the analysis. For example, if 2 µL of sample is aspirated into a conductive tip, the volume of sample not consumed can be returned to the well after analysis. In addition, because a dedicated nozzle and pipette tips were used for each analysis, the possibility of cross-contamination was eliminated. System stability and reproducibility have been shown to be robust and reliable. 27 Figures 1a-e and 2a-e show the results of the noncovalent interaction between H-FABP and A-FABP with potential ligands. When binding occurred, new peaks corresponding to the protein + ligand complex appeared in the spectra. A comparison of the mass spectra before and after addition of ligand immediately reveals if a mass shift has occurred, indicating ligand binding. It should be fairly easy, with minimal software programming, to achieve an automatic confirmation of binding. Spectra 1b and 2b in Figures 1 and 2 show identical peak patterns with the H-FABP and A-FABP proteins alone, indicating that binding of ligand 647 had occurred. On the other hand, spectra 1c-e and 2c-e show a mass shift, indicating binding of the ligands (592, 681, and 1794). Furthermore, the binding strength of the noncovalent complex can be estimated by comparing the spectra of different protein-ligand complexes with the intensity of the free protein signal. Comparison of spectra 1c and 1d shows that ligand 592 has a higher binding affinity to H-FABP than ligand 681 due to the lower relative response of the m/z 2026 peak (corresponding to the protein without ligand).
To obtain the relative or the absolute values of the binding affinities (K d ), competitive binding studies 10,28 would have to be performed.
An important parameter for high-throughput ligand screening is the total time for a single analysis. In the method described, a 1.0min acquisition time and 0.8-min robot cycle time add up to a total analysis time of 1.8 min. The current firmware for the NanoMate was not able to further reduce the cycle time between separate sample deliveries. Successful attempts with shorter, 0.3-min acquisition times were obtained, giving a total cycle time per analysis time of 1.1 min (data not shown). To speed up the screening process even more, analyses of ligand mixtures could be used. To successfully perform these analyses, the compound mixture has to be carefully designed to avoid the formation of protein-ligand complexes with the same Thomson (m/z) value. Figure 3b shows the spectrum obtained from the analysis of human H-FABP and a compound mixture containing 7 compounds, including 1 known ligand. The result clearly shows that a protein-ligand complex was formed with only 1 ligand in the compound mixture. Although sensitivity was decreased, it was possible to detect and identify the binding ligand in the mixture of compounds. The theoretical molecular mass of this ligand was 168 Da. The shift in molecular mass (169 Da) of the protein-ligand complex, shown in Figure 3b , corresponds well with the theoretical molecular mass of the ligand. The reason for the decreased sensitivity was probably due to a quenching effect by all the negatively charged acidic compounds present in the sample mixture, having a pH of 6.7. Even though compound mixtures were successfully analyzed, it is our belief that singlecompound analyses are preferable, provided the cycle times can be kept short. This is because, first, it takes time to design compound mixtures that provide unique mass shifts for each potential ligand. Second, it often is more difficult to interpret results from the mixtures. In the case of competitive binding, nonspecific binding and incompatibility between compounds will definitely make the interpretation of the noncovalently bound complexes more problem- atic. Finally, the decrease in sensitivity requires higher protein concentrations, which increases the overall protein consumption. The results from the nano-ESI/MS screening set were compared to the data, which were obtained from a structure-based screening by NMR. 23 We used the same ligands for screening as in the NMR study. As shown in Table 1 , the correlation between the 2 methods is excellent. Only the potential ligand 2500 did not show a correlation between the 2 methods. The ligand was identified as a hit by the NMR screen but not in the MS. This may reflect a different affinity cutoff between the 2 methods. The ligand 2500 was detected as a very weak binder using NMR (alternatively, it was a nonspecific binder). On the other hand, a very weak binding in the MS screen could be masked by the other adduct ions present in the spectra. Although the protein spectra were complex due to adduct ions, the mass increment (∆M) between the noncovalent complex peaks and the initial protein peak correlated well with the theoretical molecular mass of each ligand (see Table 1 ).
As mentioned earlier, the relative binding strength can be estimated by observing the relative response of the original free protein. If a protein-ligand complex appears, and the protein peak is reduced by 60% to 70%, it is reasonable to assume that the ligand is a potentially strong binder. As shown in Table 1 , ligands 592, 3081, 3084, 4033, and 4038; BVT.1961; and the compound mixture could be classified as potentially strong binders.
Interestingly, the study reveals a selectivity difference between ligands 3081 and 3084 and the different FABP proteins. The unambiguous detection of a selectivity difference between H-FABP (heart) and A-FABP (adipose) is crucial for the development of new drugs for diabetes and/or obesity.
Sample throughput and protein consumption
The described system has the potential to analyze 55 samples per hour. The NanoMate can hold only a single 96-well plate, which means that the well plate has to be changed manually every 1.8 h, giving a total sample throughput per working day (8 h) of approximately 430 samples. The sample volume used was 4 µL, which means that the total amount of protein per analysis (well) was 88 to 100 picomoles. However, it is possible to recover a protein that is mixed with a ligand by denaturation, combined with a wash step followed by refolding of the protein. 29 Using this approach, protein consumption will be in the range of 1 to 2 pmol/ analysis (22 µM • 0.2 µL/min • 0.3 min).
Nonspecific versus specific protein-ligand interaction
As pointed out earlier, nonspecific interactions of metal adduct ions such as sodium, potassium, and so on are very common during noncovalent ESI-MS analysis of macromolecules. 20, 30 Other larger molecules may also bind to a target molecule in a nonspecific manner. Jorgensen et al. 31 recently showed nonspecific interactions between peptides and vancomycin. It is well known that high concentrations of small molecules, especially acids, during ESI-MS may give rise to dimer, trimer, and n-mer association in the electrospray ion source. Figure 4a shows the spectrum of the +8 charge state, obtained from a 27-µM solution of H-FABP. The 3 largest peaks in the spectrum correspond to the molecular mass of the protein ([H-FABP + 8H + ] 8+ ), the noncovalent complex between H-FAPB and acetic acid ([H-FABP + 8H + + HAc] 8+ ), and the noncovalent complex, the base peak, between H-FAPB and the natural ligand L 1 ([H-FABP + 9H + + L 1 − ] 8+ ). The complexes with acetic acid will always be present due to the high concentration of NH 4 OAc (10 mM). HAc adduct ions are also present as the most prominent peaks in the spectrum of A-FABP ( Fig. 2a ). Furthermore, there are also complex peaks that correspond to the combination of both HAc and NH 3 adduct ions. However, the presence of adduct ion peaks in the spectra will not make the identification of potential binders more difficult. In the case of ligand binding, all peaks will be moved to a higher Thomson value that corresponds to the molecular mass of the ligand. The identity of the natural ligand in H-FABP has not yet been determined. However, it is a compound with a molecular mass of 256 Da. Because fatty acids are known ligands to FABPs, 16 palmitic acid is a likely candidate, having a molecular mass of 256 Da with a relatively high binding affinity to FABPs. 32 Figure 4b shows the situation when ligand 592 has been added to the protein solution. A change in the peak pattern shows that binding has occurred. The base peak has shifted to the noncovalent complex with the new ligand, the competitive one ([H-FABP + 9H + + L 2 − ] 8+ ). In addition, complexes with 2 ([H-FABP + 10H + + 2L 2 − ] 8+ ) and 3 ([H-FABP + 11H + +3L 2 − ] 8+ ) ligands L 2 are also observed. We observed that many of the binders (low molecular mass acids), especially the potentially strong binders, showed similar behavior. One reason for this could be that the acid molecules form clusters in the solution, whereby one of the molecules binds in the active site of the protein and the others are in the vicinity of the active site. Moreover, the nonbinding ligands did not result in nonspecific protein-ligand interactions. The peak ratio between the complex of the natural ligand L 1 and the molecular ion of the protein was decreased from approximately 4:1 to 3:1 after the addition of L 2 . This identifies the system as a competitive ligand and can be regarded as a specific binder. If a noncompetitive situation were the case, one could be doubtful about the binding characteristics. It is important to keep in mind that screening with noncovalent ESI-MS as well as screening by NMR may result in false-positive nonspecific ligands. However, it is interesting to note that compared to the NMR study, no false-positive ligands were identified with the described automated nano-ESI MS method.
In general, NMR and MS screening approaches based on noncovalent interaction have advantages over traditional highthroughput methods, such as fluorescence, in which a labeled ligand may bind differently compared to the same ligand without a label, giving false results. The MS screening approach shows a higher sensitivity and speed compared to NMR. Other features of the MS approach are the ability to obtain information on the stoichiometric ratio of the protein-ligand complex. Also, a direct measurement of the actual complex is carried out, and a ligand bound to a protein impurity is easily detected. On the other hand, an attractive feature of NMR is that the binding site of the ligand can be determined.
CONCLUSIONS
The automatic nano-ESI/MS method offers an important new platform for compound library screening with high sensitivity and reproducibility. Furthermore, nano-ESI allowed us to detect the intact gas phase noncovalent complexes of A-FABP with potential drug candidates that were not possible with nano-ESI, using conventional pulled glass capillaries. Automatic nano-ESI/MS has the potential to serve as a complementary screening method to conventional HTS. Alternatively, it could be used as a first screening method in an early phase of drug development programs, in which only small amounts of purified protein are available. The results from the MS screening were in excellent correlation with the results from a recently published study using NMR screening. Moreover, we have also shown the possibility of using compound mixtures for screening, which dramatically accelerate the screening process and consequently decrease the time for drug candidate selection. Our screening method showed a sample capacity of 2200 samples/week (single-compound analysis) combined with low protein consumption. The analysis time was approximately 50 times faster than NMR for single compounds and approximately 5 times faster for mixtures. In addition, a novel protocol for preparation of A-FABP without the natural ligand was presented. 
